Treatment of Qualitative Platelet Disorders
Diagnostic Considerations
- Flow cytometry screening should be performed using antibodies against major platelet glycoproteins (GPIIb/IIIa, GPIIIa, GPIb, GPIb/IX) to identify specific platelet defects, and assessment of granule release (α and δ granules) is necessary to detect secretion defects that may require specific treatment approaches in patients with qualitative platelet disorders 1
General Treatment Strategies
- Consider the specific type of platelet function disorder when selecting treatment, as different disorders may respond differently to various interventions, according to the International Society on Thrombosis and Haemostasis 1, 2
Treatment Options for Specific Disorders
Storage Pool Disorders (SPD)
- Patients with δ-storage pool disease (δ-SPD) often respond to platelet transfusions during significant bleeding episodes 1
- For patients with α-granule deficiency (Gray Platelet Syndrome) or combined α-δ granule defects, a combination approach with antifibrinolytic agents and platelet transfusions may be necessary 1
Signaling Pathway Defects
- Patients with defects in platelet signaling pathways (such as P2Y12 defects or thromboxane synthesis defects) may benefit from platelet transfusions during bleeding episodes 1
- For cyclooxygenase-1 deficiency or thromboxane synthase deficiency, avoid medications that further impair the arachidonic acid pathway 1
Preventive Measures
- Regular monitoring of platelet function in patients with known qualitative disorders is recommended to assess disease progression and treatment response, as suggested by the International Society on Thrombosis and Haemostasis 1, 2
Diagnostic Approach and Management of Inherited Platelet Disorders
Diagnostic Tests
- The International Society on Thrombosis and Haemostasis recommends confirming true thrombocytopenia with peripheral blood smear examination to assess platelet morphology, size, and variation 3
- The British Committee for Standards in Haematology suggests performing light transmission aggregometry (LTA) with standard agonists (ADP, collagen, epinephrine, ristocetin) to evaluate platelet function 4, 5
- Flow cytometry screening on resting platelets using antibodies against GPIIb/IIIa (CD41), GPIIIa (CD61), GPIb (CD42b), and GPIb/IX (CD42a) is recommended to evaluate platelet glycoproteins 4, 5, 6, 7
- Evaluation of granule release (α and δ granules) to detect secretion defects is suggested 7
Treatment Strategies
- The American Society of Anesthesiologists recommends avoiding medications that impair platelet function (aspirin, NSAIDs) for mild bleeding or prophylaxis 8
- A target minimum platelet count of 75 × 10^9/L during active bleeding is recommended 8
Special Considerations
- Patients with Wiskott-Aldrich syndrome may present with small (not large) platelets and thrombocytopenia, according to the American Academy of Allergy, Asthma, and Immunology 9
- Some patients may have normal platelet counts but abnormal platelet function, as noted by the International Society on Thrombosis and Haemostasis 5, 7
Platelet Function Testing Guidelines
First-Step Testing Approach
- The International Society on Thrombosis and Haemostasis recommends a structured diagnostic algorithm that explicitly excludes bleeding time due to insufficient specificity and sensitivity, and suggests Light Transmission Aggregometry (LTA) with standard agonists as the gold standard first-line test for assessing platelet function 10, 11, 12
- The International Society on Thrombosis and Haemostasis recommends flow cytometry screening on both resting and activated platelets using antibodies against GPIIb/IIIa, GPIIIa, GPIb, GPIb/IX, and PAC-1 for diagnosing platelet function disorders 10, 11, 13
- The first-step combination of LTA and flow cytometry requires approximately 21-28 mL of blood and can diagnose up to 40% of inherited platelet function disorders 10, 12
Second-Step Testing
- If initial testing doesn't establish a diagnosis but clinical suspicion remains high, an expanded LTA panel with additional agonists and expanded flow cytometry evaluating GPIa/IIa, GPIV, and GPVI should be performed 10, 11, 13
- A clot retraction test by incubating non-anticoagulated whole blood for 60 minutes at 37°C in glass tubes can also be used to detect platelet function disorders 10, 14, 15
- Serum thromboxane B2 measurement by ELISA or RIA can detect arachidonic acid pathway defects 10, 14, 15
- Transmission electron microscopy for counting α-granules and dense-granules and identifying structural abnormalities can also be used 10, 11, 14
Third-Step Testing
- For undiagnosed cases with strong clinical suspicion, biochemical studies, receptor binding assays, and molecular genetics studies can be performed in specialized centers 11, 12, 16
- These third-step tests require 40-50 mL of blood and are available only in specialized centers 11, 12
Practical Considerations
- Repeat platelet studies should be separated by at least 1 month to allow disappearance of acquired interfering factors 14, 15, 16
Diagnostic Approach for Inherited Platelet Disorders
Initial Clinical Assessment
- The International Society on Thrombosis and Haemostasis recommends documenting specific bleeding manifestations that suggest inherited platelet disorders, such as unexplained or extensive bruising from early childhood, severe epistaxis requiring medical intervention, menorrhagia in females, and bleeding following dental extractions or invasive procedures 17
- A validated bleeding assessment tool (BAT) should be used to quantify bleeding severity, as this has proven validity in identifying patients requiring platelet function testing 17
Diagnostic Testing
- The American Society of Hematology recommends diagnosing Bernard-Soulier syndrome (BSS) by demonstrating deficient GPIb/IX expression on flow cytometry combined with absent ristocetin-induced platelet aggregation, and diagnosing Glanzmann thrombasthenia (GT) by showing deficient GPIIb/IIIa expression on flow cytometry with absent aggregation to all agonists except ristocetin 18, 19
- For BSS, light transmission aggregometry (LTA) typically shows normal aggregation to ADP, collagen, and arachidonic acid, but absent aggregation to ristocetin 18, 19
- For GT, LTA typically shows absent or severely reduced aggregation (<30%) to ADP, collagen, and arachidonic acid, but normal aggregation to ristocetin 18, 19
- Flow cytometry is essential for definitive diagnosis and can be performed on small blood volumes, making it particularly suitable for pediatric patients, using antibodies against GPIb (CD42b) and GPIb/IX (CD42a) for BSS, and against GPIIb/IIIa (CD41), GPIIIa (CD61) for GT 18, 19
Molecular Confirmation
- Genetic testing can identify specific mutations, with BSS associated with mutations in GP9, GP1BA, or GP1BB genes, and GT associated with mutations in ITGA2B or ITGB3 genes 18, 19